Several types of human tumour are dependent on mutations in BRAF. This led to the development of RAF inhibitors, which prolong patient survival but are limited by resistance. This Review discusses the recent advances in our understanding of BRAF oncogenic signalling, RAF inhibitor activity and the implementation of this knowledge for the development of next-generation inhibitors.
- Zoi Karoulia
- Evripidis Gavathiotis
- Poulikos I. Poulikakos